The Advanced Technology Center, Sheba Medical Center, Ramat-Gan, 52621, Israel.
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.
Sci Rep. 2020 Feb 7;10(1):2178. doi: 10.1038/s41598-020-59152-7.
The prognosis of Glioblastoma Multiforme patients is poor despite aggressive therapy. Reasons include poor chemotherapy penetration across the blood-brain barrier and tumor infiltration into surrounding tissues. Here we studied the effects of combined point-source electroporation (EP) and systemic chemotherapy in glioma-bearing rats. 128 rats were studied. Treatment groups were administered systemic Cisplatin/Methotrexate before EP (either 90 or 180 pulses). Control groups were treated by EP, chemotherapy, or no treatment. Tumor volumes were determined by MRI. Tumors growth rates of the EP + Methotrexate group (1.02 ± 0.77) were significantly lower (p < 0.01) than the control (5.2 ± 1.0) 1-week post treatment. No significant difference was found compared to Methotrexate (1.7 ± 0.5). Objective response rates (ORR) were 40% and 57% for the Methotrexate and EP + Methotrexate groups respectively. Tumor growth rates and ORR of the EP + Cisplatin groups (90 pulses 0.98 ± 0.2, 57%, 180 pulses 1.2 ± 0.1, 33%) were significantly smaller than the control (6.4 ± 1.0, p < 0.01, p < 0.02, 0%) and Cisplatin (3.9 ± 1.0, p < 0.04, p < 0.05, 13%) groups. No significant differences were found between the control groups. Increased survival was found in the EP + Cisplatin group, Χ = 7.54, p < 0.006 (Log Rank). Point-source EP with systemic chemotherapy is a rapid, minimal-invasive treatment that was found to induce significant antineoplastic effects in a rat glioma model.
尽管采用了积极的治疗方法，胶质母细胞瘤患者的预后仍然很差。原因包括血脑屏障通透性差和肿瘤浸润周围组织。在这里，我们研究了联合点源电穿孔（EP）和系统化疗对荷瘤大鼠的影响。研究了 128 只大鼠。实验组在 EP 前给予系统顺铂/甲氨蝶呤（90 或 180 个脉冲）。对照组给予 EP、化疗或不治疗。通过 MRI 确定肿瘤体积。EP+甲氨蝶呤组（1.02±0.77）的肿瘤生长率明显低于对照组（5.2±1.0），治疗后 1 周（p<0.01）。与甲氨蝶呤组（1.7±0.5）相比，无显著差异。甲氨蝶呤组和 EP+甲氨蝶呤组的客观缓解率（ORR）分别为 40%和 57%。EP+顺铂组（90 脉冲 0.98±0.2，57%，180 脉冲 1.2±0.1，33%）的肿瘤生长率和 ORR 明显小于对照组（6.4±1.0，p<0.01，p<0.02，0%）和顺铂组（3.9±1.0，p<0.04，p<0.05，13%）。对照组之间无显著差异。EP+顺铂组的生存时间延长，Χ=7.54，p<0.006（对数秩）。点源 EP 联合全身化疗是一种快速、微创的治疗方法，在大鼠脑胶质瘤模型中发现具有显著的抗肿瘤作用。
